Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation

被引：5
|
作者：
Wolf, J. [1 ]
Heist, R. [2 ]
Kim, T. M. [3 ]
Nishio, M. [4 ]
Dooms, C. [5 ]
Kanthala, R. R. [6 ]
Leo, E. [7 ]
Giorgetti, E. [7 ]
Wang, Y. [8 ]
Mardjuadi, F. I. [8 ]
Cortot, A. [9 ]
机构：
[1] Univ Klinikum Koln AoR, Dept Internal Med 1, Ctr Integrated Oncol, Cologne, Germany
[2] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA
[3] Seoul Natl Univ, Coll Med, Dept Internal Med, Yeongeon Med Campus, Seoul, South Korea
[4] JFCR, Canc Inst Hosp, Dept Thorac Med Oncol, Koto Ku, Tokyo, Japan
[5] Univ Hosp Leuven, UZ Leuven, Dept Resp Dis, Campus Gasthuisberg, Leuven, Belgium
[6] Novartis Healthcare Pvt Ltd, GDO DO Stat Programming, Hyderabad, Telangana, India
[7] Novartis Pharma AG, Oncol, Basel, Switzerland
[8] Novartis Inst BioMed Res Co Ltd, Oncol, Shanghai, Peoples R China
[9] Univ Lille, CHU Lille, Thorac Oncol Dept,Inst Pasteur Lille, CNRS,Inserm,UMR9020,UMR S 1277 Canther, Lille, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
994P
引用
收藏
页码：S1007 / S1008
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
    Garassino, M. C. C.
    Felip, E.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E. F. F.
    Mazieres, J.
    Cortot, A. B.
    Raskin, J.
    Thomas, M.
    Viteri, S.
    Iams, W. T.
    Kim, H. R.
    Yang, J.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S984 - S985
  • [22] Novel MET Exon 14 Skipping Treatment-Naive Lung Adenocarcinoma Presented Primary Resistance to Crizotinib
    Jiang, Wenjuan
    Yang, Nong
    Zhang, Yongchang
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : E124 - E126
  • [23] Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.
    Lau, Sally C. M.
    Perdrizet, Kirstin
    Mata, Danilo Giffoni de Mello Morais
    Fung, Andrea S.
    Liu, Geoffrey
    Bradbury, Penelope Ann
    Shepherd, Frances A.
    Sacher, Adrian G.
    Sheffield, Brandon
    Hwang, David
    Tsao, Ming Sound
    Cheng, Susanna Y.
    Cheema, Parneet
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
    Choi, Wonyoung
    Park, Seog-Yun
    Lee, Youngjoo
    Lim, Kun Young
    Park, Minjoung
    Lee, Geon Kook
    Han, Ji-Youn
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 1024 - 1032
  • [25] Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Le, X.
    Cho, B. C.
    Han, J-Y.
    Morise, M.
    Chen, Y-M.
    Kang, J-H.
    Kato, T.
    Takeoka, H.
    Chikamori, K.
    Sakai, H.
    Park, K.
    Wu, Y-L.
    Schumacher, K.
    Bruns, R.
    Straub, J.
    Paik, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1390 - S1391
  • [26] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.
    Kato, Terufumi
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Sakai, Hiroshi
    Morise, Masahiro
    Chen, Yuh-Min
    Han, Ji-Youn
    Yang, Jin-Ji
    Zhao, Jun
    Huang, Jason
    Berghoff, Karin
    Bruns, Rolf
    Vioix, Helene
    Otto, Gordon
    Le, Xiuning
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] MET amplification and exon 14 skipping in treatment naive patients in lung cancer.
    Han, Yaqian
    Xu, Ying
    Liu, Chunling
    Zhao, Jun
    Zhu, Lingjun
    Li, Liren
    Gen, Lin
    Liu, Lianke
    Cheng, Yong
    Ye, Ke
    Chen, Likun
    Zhang, Longbo
    Yu, Fenglei
    Du, Kaiqi
    Miao, Liyun
    Chen, Rongrong
    Xia, Xuefeng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Real-world assessment of clinical outcomes in NSCLC patients with MET exon 14 skipping mutation and brain metastases (BM) treated with capmatinib.
    Paik, Paul K.
    Goyal, Ravi K.
    Cai, Beilei
    Price, Mark
    Davis, Keith
    Ansquer, Valerie Derrien
    Caro, Nydia
    Saliba, Teddy Rassem
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Scherz, A.
    Felip, E.
    Garassino, M.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Viteri, S.
    Iams, W. Thomas
    Kim, H. R.
    Yang, J. -J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    SWISS MEDICAL WEEKLY, 2021, 151 : 36 - 36
  • [30] Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A
    Mazieres, J.
    Paik, P.
    Felip, E.
    Veillon, R.
    Sakai, H.
    Cortot, A.
    Viteri, S.
    Garassino, M.
    Van Meerbeeck, J.
    Raskin, J.
    Thomas, M.
    Morise, M.
    Cho, B. C.
    Conte, P.
    Bruns, R.
    Demuth, T.
    Schumacher, K. M.
    Le, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S5 - S5
12345